91 related articles for article (PubMed ID: 26935630)
1. [Chemokines in chronic myeloid leukemia].
Mukaida N; Baba T
Rinsho Ketsueki; 2016 Feb; 57(2):129-36. PubMed ID: 26935630
[TBL] [Abstract][Full Text] [Related]
2. Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia.
Mukaida N; Tanabe Y; Baba T
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829353
[TBL] [Abstract][Full Text] [Related]
3. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
4. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
Møller GM; Frost V; Melo JV; Chantry A
FEBS Lett; 2007 Apr; 581(7):1329-34. PubMed ID: 17349636
[TBL] [Abstract][Full Text] [Related]
6. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
[TBL] [Abstract][Full Text] [Related]
7. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.
Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C
Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715
[TBL] [Abstract][Full Text] [Related]
8. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
[TBL] [Abstract][Full Text] [Related]
9. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
Chu S; Li L; Singh H; Bhatia R
Cancer Res; 2007 Jul; 67(14):7045-53. PubMed ID: 17638918
[TBL] [Abstract][Full Text] [Related]
10. Alterations in the bone marrow microenvironment may elicit defective hematopoiesis: a comparison of aplastic anemia, chronic myeloid leukemia, and normal bone marrow.
Park M; Park CJ; Cho YW; Jang S; Lee JH; Lee JH; Lee KH; Lee YH
Exp Hematol; 2017 Jan; 45():56-63. PubMed ID: 27693387
[TBL] [Abstract][Full Text] [Related]
11. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity.
Xu R; Dong Q; Yu Y; Zhao X; Gan X; Wu D; Lu Q; Xu X; Yu XF
Leuk Res; 2006 Jan; 30(1):17-23. PubMed ID: 16023722
[TBL] [Abstract][Full Text] [Related]
12. Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia.
Kabarowski JH; Witte ON
Stem Cells; 2000; 18(6):399-408. PubMed ID: 11072027
[TBL] [Abstract][Full Text] [Related]
13. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Buchdunger E
Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C
Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463
[TBL] [Abstract][Full Text] [Related]
15. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.
Hiwase DK; White DL; Powell JA; Saunders VA; Zrim SA; Frede AK; Guthridge MA; Lopez AF; D'Andrea RJ; To LB; Melo JV; Kumar S; Hughes TP
Leukemia; 2010 Apr; 24(4):771-8. PubMed ID: 20130598
[TBL] [Abstract][Full Text] [Related]
16. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
[TBL] [Abstract][Full Text] [Related]
17. Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells.
Xu Y; Ikeda S; Sumida K; Yamamoto R; Tanaka H; Minato N
Nat Commun; 2018 Mar; 9(1):914. PubMed ID: 29500416
[TBL] [Abstract][Full Text] [Related]
18. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation.
Barnes K; McIntosh E; Whetton AD; Daley GQ; Bentley J; Baldwin SA
Oncogene; 2005 May; 24(20):3257-67. PubMed ID: 15735728
[TBL] [Abstract][Full Text] [Related]
19. Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles.
Ramos TL; Sánchez-Abarca LI; López-Ruano G; Muntión S; Preciado S; Hernández-Ruano M; Rosado B; de las Heras N; Chillón MC; Hernández-Hernández Á; González M; Sánchez-Guijo F; Del Cañizo C
Leuk Res; 2015 Aug; 39(8):921-4. PubMed ID: 26105049
[TBL] [Abstract][Full Text] [Related]
20. Leukemia stem cells: the root of chronic myeloid leukemia.
Zhou H; Xu R
Protein Cell; 2015 Jun; 6(6):403-12. PubMed ID: 25749979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]